JP2009529502A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009529502A5 JP2009529502A5 JP2008557568A JP2008557568A JP2009529502A5 JP 2009529502 A5 JP2009529502 A5 JP 2009529502A5 JP 2008557568 A JP2008557568 A JP 2008557568A JP 2008557568 A JP2008557568 A JP 2008557568A JP 2009529502 A5 JP2009529502 A5 JP 2009529502A5
- Authority
- JP
- Japan
- Prior art keywords
- dosage form
- form according
- scyllo
- inositol
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002552 dosage form Substances 0.000 claims 12
- 230000003941 amyloidogenesis Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 claims 4
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 230000007082 Aβ accumulation Effects 0.000 claims 2
- 238000009825 accumulation Methods 0.000 claims 2
- 238000004220 aggregation Methods 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 2
- 208000010877 cognitive disease Diseases 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 230000002688 persistence Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000002776 aggregation Effects 0.000 claims 1
- 238000011257 definitive treatment Methods 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 230000001771 impaired effect Effects 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000003405 preventing effect Effects 0.000 claims 1
- 230000004845 protein aggregation Effects 0.000 claims 1
- 230000012846 protein folding Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78052606P | 2006-03-09 | 2006-03-09 | |
| US81986406P | 2006-07-11 | 2006-07-11 | |
| US89766707P | 2007-01-26 | 2007-01-26 | |
| PCT/CA2007/000395 WO2007101353A1 (en) | 2006-03-09 | 2007-03-09 | A cyclohexane polyalcohol formulation for treatment of disorders of protein aggregation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009529502A JP2009529502A (ja) | 2009-08-20 |
| JP2009529502A5 true JP2009529502A5 (enExample) | 2011-04-14 |
Family
ID=38474578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008557568A Pending JP2009529502A (ja) | 2006-03-09 | 2007-03-09 | タンパク質凝集の障害の処置のためのシクロヘキサン多価アルコール処方物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20100113613A1 (enExample) |
| EP (1) | EP1996175A4 (enExample) |
| JP (1) | JP2009529502A (enExample) |
| KR (1) | KR20090026247A (enExample) |
| CN (1) | CN103054837A (enExample) |
| AU (1) | AU2007222864A1 (enExample) |
| BR (1) | BRPI0708725A2 (enExample) |
| CA (1) | CA2644804A1 (enExample) |
| EA (1) | EA200801967A1 (enExample) |
| IL (1) | IL193970A0 (enExample) |
| MX (1) | MX2008011553A (enExample) |
| NZ (1) | NZ571181A (enExample) |
| WO (1) | WO2007101353A1 (enExample) |
| ZA (1) | ZA200908303B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| WO2008034244A1 (en) * | 2006-09-21 | 2008-03-27 | Waratah Pharmaceuticals Inc. | The combination of a cyclohexanehexol and a nsaid for the treatment of neurodegenerative diseases |
| CA2670405A1 (en) * | 2006-11-24 | 2008-05-29 | Waratah Pharmaceuticals Inc. | Combination treatments for alzheimer's disease and related neurodegenerative diseases |
| DE102007030695A1 (de) * | 2007-07-01 | 2009-01-08 | Sciconcept Gmbh | Co-Kristalle aus Harnstoff mit Amid- und/oder Harnstoffderivaten |
| US9925282B2 (en) | 2009-01-29 | 2018-03-27 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| CA2837926A1 (en) * | 2011-06-03 | 2012-12-20 | Susan ABUSHAKRA | Scyllo - inositol for the treatment of behavioral and psychiatric disorders |
| US10058530B2 (en) | 2012-10-25 | 2018-08-28 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
| US9855276B2 (en) | 2012-10-25 | 2018-01-02 | The General Hospital Corporation | Combination therapies for the treatment of Alzheimer's disease and related disorders |
| AU2014225534A1 (en) * | 2013-03-06 | 2015-09-24 | Acorda Therapeutics, Inc. | Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure |
| US10525005B2 (en) | 2013-05-23 | 2020-01-07 | The General Hospital Corporation | Cromolyn compositions and methods thereof |
| EP3060205A4 (en) | 2013-10-22 | 2017-06-28 | The General Hospital Corporation | Cromolyn derivatives and related methods of imaging and treatment |
| CN116889562A (zh) | 2016-08-31 | 2023-10-17 | 通用医疗公司 | 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞 |
| MX2020000577A (es) | 2017-07-20 | 2020-09-10 | Aztherapies Inc | Formulaciones en polvo de cromolina sodica e ibuprofeno. |
| CA3105392A1 (en) | 2018-07-02 | 2020-01-09 | The General Hospital Corporation | Powdered formulations of cromolyn sodium and .alpha.-lactose |
| CA3113377A1 (en) | 2018-10-11 | 2020-04-16 | Sanifit Therapeutics S.A. | Inositol phosphates for the treatment of ectopic calcification |
| AU2019397436A1 (en) | 2018-12-10 | 2021-07-22 | The General Hospital Corporation | Cromolyn esters and uses thereof |
| WO2021207060A1 (en) | 2020-04-06 | 2021-10-14 | The General Hospital Corporation | Methods of treatment of coronavirus-induced inflammation conditions |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4454151A (en) * | 1982-03-22 | 1984-06-12 | Syntex (U.S.A.) Inc. | Use of pyrrolo pyrroles in treatment of ophthalmic diseases |
| US4515722A (en) * | 1982-03-30 | 1985-05-07 | Merck & Co., Inc. | Phosphatidyl inositol analogs useful as anti-inflammatory/analgesic agents |
| US4474806A (en) * | 1982-05-10 | 1984-10-02 | Merck & Co., Inc. | Sulfonyl or carbonyl inositol derivatives useful as anti-inflammatory/analgesic agents |
| US4952396A (en) * | 1986-11-19 | 1990-08-28 | Linus Pauling Institute Of Science & Medicine | Method of using phytic acid for inhibiting tumor growth |
| US4847082A (en) * | 1987-01-21 | 1989-07-11 | Robert Sabin | Method of treatment of Alzheimer's disease using phytic acid |
| US4758430A (en) * | 1987-01-21 | 1988-07-19 | Robert Sabin | Method of treatment of Alzheimer's disease using phytic acid |
| SE8904355D0 (sv) * | 1989-12-21 | 1989-12-21 | Perstorp Ab | Medicament |
| US5217959A (en) * | 1990-09-06 | 1993-06-08 | Robert Sabin | Method of treating multiple sclerosis with phytic acid |
| US5112814A (en) * | 1990-10-24 | 1992-05-12 | Robert Sabin | Method of treatment of Parkinson's disease using phytic acid |
| KR0185215B1 (ko) * | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
| SE9102068L (sv) * | 1991-07-03 | 1993-01-04 | Perstorp Ab | Derivat av inositol, kompositioner innehaallande dessa samt anvaendning daerav |
| SE469260B (sv) * | 1992-02-25 | 1993-06-14 | Perstorp Ab | En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat |
| NZ256610A (en) * | 1992-10-05 | 1997-03-24 | Virginia Tech Intell Prop | Synthesis of epoxydiol intermediates in the preparation of inositols and inosose; epoxydiols |
| US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| US5643562A (en) * | 1993-03-29 | 1997-07-01 | Queen's University Of Kingston | Method for treating amyloidosis |
| US5972328A (en) * | 1993-03-29 | 1999-10-26 | Queen's University At Kingston | Method for treating amyloidosis |
| DK0619369T3 (da) * | 1993-04-05 | 2003-10-06 | Aveve Nv | Phytathydrolyse og enzymsammensætning til hydrolyse af phytat |
| ATE176779T1 (de) * | 1993-08-11 | 1999-03-15 | Hokko Chem Ind Co | Verfahren zur herstellung von d-chiro inositol |
| SE502574C2 (sv) * | 1994-01-25 | 1995-11-13 | Perstorp Ab | En farmaceutisk komposition med förbättrad biotillgänglighet hos inositolfosfat |
| US5858326A (en) * | 1995-06-06 | 1999-01-12 | Neurochem, Inc. | Methods of increasing amyloid deposition |
| US5756541A (en) * | 1996-03-11 | 1998-05-26 | Qlt Phototherapeutics Inc | Vision through photodynamic therapy of the eye |
| US6232486B1 (en) * | 1996-06-11 | 2001-05-15 | Nutrimed Biotech | Molecular probes and modulators for PI-PLC and PI 3-kinase |
| US5880099A (en) * | 1996-09-20 | 1999-03-09 | The Regents Of The University Of California | Inositol polyphosphates and methods of using same |
| US5977078A (en) * | 1996-09-20 | 1999-11-02 | The Regents Of The Univesity Of California | Inositol polyphosphate derivatives and methods of using same |
| US5998485A (en) * | 1997-06-16 | 1999-12-07 | Cedars-Sinai Medical Center | Method for modulating immune response with inositol |
| US6153603A (en) * | 1997-06-27 | 2000-11-28 | Perstorp Ab | Method of treating angiogenesis in tumor tissue |
| US6310073B1 (en) * | 1998-07-28 | 2001-10-30 | Queen's University At Kingston | Methods and compositions to treat glycosaminoglycan-associated molecular interactions |
| US6818430B1 (en) * | 1999-06-07 | 2004-11-16 | Hokko Chemical Industry Co., Ltd. | Process for producing L-epi-2-inosose and novel process for producing epi-inositol |
| US6329256B1 (en) * | 1999-09-24 | 2001-12-11 | Advanced Micro Devices, Inc. | Self-aligned damascene gate formation with low gate resistance |
| JP2003511094A (ja) * | 1999-10-18 | 2003-03-25 | マッスルテク リサーチ アンド ディヴェロプメント インコーポレーション | 無脂肪体重及び体力を増強するための食物補充物質 |
| US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
| DE10031955A1 (de) * | 2000-06-30 | 2002-01-17 | Deutsches Krebsforsch | Curcumin-Derivate mit gegenüber Curcumin verbesserter Wasserlöslichkeit und diese enthaltende Arzneimittel |
| CA2437563C (en) * | 2001-02-06 | 2010-03-23 | Qlt Inc. | Photodynamic therapy of occult age-related macular degeneration |
| US7060695B2 (en) * | 2001-02-06 | 2006-06-13 | Qlt, Inc. | Method to prevent vision loss |
| US20030181531A1 (en) * | 2003-02-11 | 2003-09-25 | David Sherris | Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases |
| US6599891B2 (en) * | 2001-07-20 | 2003-07-29 | Qlt Inc. | Treatment of macular edema |
| US20040058313A1 (en) * | 2002-04-24 | 2004-03-25 | Abreu Marcio Marc | Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
| US7521481B2 (en) * | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| DK2058390T3 (da) * | 2003-10-14 | 2013-05-06 | Hokko Chem Ind Co | Fremgangsmåde til fremstilling af scyllo-inositol |
| ZA200704872B (en) * | 2004-11-17 | 2008-12-31 | Mclaurin Joanne | Compositions comprising scyllo-inositol derivatives and methods to treat disorders of protein aggregation |
-
2007
- 2007-03-09 CA CA002644804A patent/CA2644804A1/en not_active Abandoned
- 2007-03-09 CN CN201210257027XA patent/CN103054837A/zh active Pending
- 2007-03-09 NZ NZ571181A patent/NZ571181A/en not_active IP Right Cessation
- 2007-03-09 EA EA200801967A patent/EA200801967A1/ru unknown
- 2007-03-09 BR BRPI0708725-0A patent/BRPI0708725A2/pt not_active IP Right Cessation
- 2007-03-09 JP JP2008557568A patent/JP2009529502A/ja active Pending
- 2007-03-09 EP EP07710726A patent/EP1996175A4/en not_active Withdrawn
- 2007-03-09 KR KR1020087024122A patent/KR20090026247A/ko not_active Ceased
- 2007-03-09 US US12/282,030 patent/US20100113613A1/en not_active Abandoned
- 2007-03-09 WO PCT/CA2007/000395 patent/WO2007101353A1/en not_active Ceased
- 2007-03-09 AU AU2007222864A patent/AU2007222864A1/en not_active Abandoned
- 2007-03-09 MX MX2008011553A patent/MX2008011553A/es not_active Application Discontinuation
-
2008
- 2008-09-08 IL IL193970A patent/IL193970A0/en unknown
-
2009
- 2009-11-24 ZA ZA2009/08303A patent/ZA200908303B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009529502A5 (enExample) | ||
| US8309535B2 (en) | Compositions and methods to treat recurrent medical conditions | |
| JP6353577B2 (ja) | 組み合わせ組成物 | |
| JP2020023518A5 (enExample) | ||
| JP2018513188A5 (enExample) | ||
| RU2010140682A (ru) | Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство | |
| JP2000515486A (ja) | アダマンタン誘導体の内耳炎治療向け使用 | |
| JP2018507243A5 (enExample) | ||
| JP2013511507A5 (enExample) | ||
| JP2019517542A5 (enExample) | ||
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP2010509326A5 (enExample) | ||
| JP2010065060A (ja) | 心不全処置のための複合治療 | |
| JP2013541583A5 (enExample) | ||
| JP5842058B2 (ja) | 自閉症の治療における使用のためのクレンブテロール | |
| JP2017533211A5 (enExample) | ||
| JP2019218379A5 (enExample) | ||
| JP2010538066A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| CA2563058C (en) | Supportive treatment of liver disease | |
| RU2008134143A (ru) | Фармацевтическая композиция цитиколина, холина альфосцерата и l-карнитина (или ацетил-l-карнитина) для лечения и профилактики заболеваний центральной нервной системы и способ лечения | |
| IL272834B1 (en) | Compositions of amantadine, their preparation, and methods of use | |
| RU2018131573A (ru) | Способ лечения больных раком с тяжелой почечной недостаточностью | |
| JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤 | |
| JP2020503318A5 (enExample) |